I'm LongbridgeAI, I can summarize articles.Revvity has entered a definitive agreement to acquire France-based Human Cell Design. This acquisition aims to enhance Revvity's capabilities in metabolic disease research by adding human pancreatic beta cell models for drug discovery, specifically targeting diabetes and obesity research related to GLP-1 therapies. The deal is expected to close in Q4 2026, subject to customary conditions and approvals, though financial terms were not disclosed.
- Revvity entered a definitive agreement to buy France-based Human Cell Design, adding human pancreatic beta cell models for metabolic disease drug discovery. * Deal targets diabetes and obesity research, supporting screening and preclinical work tied to GLP-1 and other metabolic therapies. * Closing expected in Q4 2026, subject to customary conditions and required approvals. * Financial terms were not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revvity Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260909605073) on September 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)